Cargando…

High resistance to reverse transcriptase inhibitors among persons infected with human immunodeficiency virus type 1 subtype circulating recombinant form 02_AG in Ghana and on antiretroviral therapy

This study sought to determine the dominant circulating human immunodeficiency virus type 1 (HIV-1) subtype and associated drug resistance mutations in Ghana. This cross-sectional study was conducted with archived samples collected from patients who received care at 2 hospitals in Ghana from 2014 to...

Descripción completa

Detalles Bibliográficos
Autores principales: Deletsu, Selase D., Maina, Edward K., Quaye, Osbourne, Ampofo, William K., Awandare, Gordon A., Bonney, Evelyn Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7035011/
https://www.ncbi.nlm.nih.gov/pubmed/32049783
http://dx.doi.org/10.1097/MD.0000000000018777
_version_ 1783499987089358848
author Deletsu, Selase D.
Maina, Edward K.
Quaye, Osbourne
Ampofo, William K.
Awandare, Gordon A.
Bonney, Evelyn Y.
author_facet Deletsu, Selase D.
Maina, Edward K.
Quaye, Osbourne
Ampofo, William K.
Awandare, Gordon A.
Bonney, Evelyn Y.
author_sort Deletsu, Selase D.
collection PubMed
description This study sought to determine the dominant circulating human immunodeficiency virus type 1 (HIV-1) subtype and associated drug resistance mutations in Ghana. This cross-sectional study was conducted with archived samples collected from patients who received care at 2 hospitals in Ghana from 2014 to 2016. Blood samples were earlier processed into plasma and peripheral blood mononuclear cells and stored at −80 °C. Ribonucleic acid (RNA) was extracted from the archived plasma. Two HIV-1 genes; protease and reverse transcriptase, were amplified, sequenced using gene-specific primers and analyzed for subtype and drug resistance mutations using the Stanford HIV Database. Of 16 patient samples successfully sequenced, we identified the predominance of HIV-1 subtype CRF02_AG (11/16, 68%). Subtypes G (2/16, 13%), dual CRF02_AG/G (2/16, 13%), and CRF01_AE (1/16, 6%) were also observed. Major nucleoside reverse transcriptase inhibitor (NRTI) resistance mutations, M184I/V, D67N, T215F, and K70R/E were found. Non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance mutations, K103N, Y181C, V90I, F227L, and V106A were also prevalent. Additionally, and at a lower level, protease inhibitor (PI)-resistance mutations, M46I, I54 V, V82A, L90 M, and I471 V, were also present in the sequences from antiretroviral therapy (ART)-experienced individuals. Two NRTI-associated drug resistance mutations (DRMs) (D67N and T69N) were present in sequences from 1 ART-naive individual. HIV-1 subtype CRF02_AG was most frequently detected in this study thus confirming earlier reports of dominance of this subtype in the West-African sub-region and Ghana in particular. The detection of these drug resistance mutations in individuals on first-line regimen composed of NRTI and NNRTI is an indication of prolonged drug exposure without viral load monitoring. Routine viral load monitoring is necessary for early detection of virologic failure and drug resistance testing will inform appropriate choice of regimens for such patients.
format Online
Article
Text
id pubmed-7035011
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-70350112020-03-10 High resistance to reverse transcriptase inhibitors among persons infected with human immunodeficiency virus type 1 subtype circulating recombinant form 02_AG in Ghana and on antiretroviral therapy Deletsu, Selase D. Maina, Edward K. Quaye, Osbourne Ampofo, William K. Awandare, Gordon A. Bonney, Evelyn Y. Medicine (Baltimore) 4850 This study sought to determine the dominant circulating human immunodeficiency virus type 1 (HIV-1) subtype and associated drug resistance mutations in Ghana. This cross-sectional study was conducted with archived samples collected from patients who received care at 2 hospitals in Ghana from 2014 to 2016. Blood samples were earlier processed into plasma and peripheral blood mononuclear cells and stored at −80 °C. Ribonucleic acid (RNA) was extracted from the archived plasma. Two HIV-1 genes; protease and reverse transcriptase, were amplified, sequenced using gene-specific primers and analyzed for subtype and drug resistance mutations using the Stanford HIV Database. Of 16 patient samples successfully sequenced, we identified the predominance of HIV-1 subtype CRF02_AG (11/16, 68%). Subtypes G (2/16, 13%), dual CRF02_AG/G (2/16, 13%), and CRF01_AE (1/16, 6%) were also observed. Major nucleoside reverse transcriptase inhibitor (NRTI) resistance mutations, M184I/V, D67N, T215F, and K70R/E were found. Non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance mutations, K103N, Y181C, V90I, F227L, and V106A were also prevalent. Additionally, and at a lower level, protease inhibitor (PI)-resistance mutations, M46I, I54 V, V82A, L90 M, and I471 V, were also present in the sequences from antiretroviral therapy (ART)-experienced individuals. Two NRTI-associated drug resistance mutations (DRMs) (D67N and T69N) were present in sequences from 1 ART-naive individual. HIV-1 subtype CRF02_AG was most frequently detected in this study thus confirming earlier reports of dominance of this subtype in the West-African sub-region and Ghana in particular. The detection of these drug resistance mutations in individuals on first-line regimen composed of NRTI and NNRTI is an indication of prolonged drug exposure without viral load monitoring. Routine viral load monitoring is necessary for early detection of virologic failure and drug resistance testing will inform appropriate choice of regimens for such patients. Wolters Kluwer Health 2020-02-14 /pmc/articles/PMC7035011/ /pubmed/32049783 http://dx.doi.org/10.1097/MD.0000000000018777 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle 4850
Deletsu, Selase D.
Maina, Edward K.
Quaye, Osbourne
Ampofo, William K.
Awandare, Gordon A.
Bonney, Evelyn Y.
High resistance to reverse transcriptase inhibitors among persons infected with human immunodeficiency virus type 1 subtype circulating recombinant form 02_AG in Ghana and on antiretroviral therapy
title High resistance to reverse transcriptase inhibitors among persons infected with human immunodeficiency virus type 1 subtype circulating recombinant form 02_AG in Ghana and on antiretroviral therapy
title_full High resistance to reverse transcriptase inhibitors among persons infected with human immunodeficiency virus type 1 subtype circulating recombinant form 02_AG in Ghana and on antiretroviral therapy
title_fullStr High resistance to reverse transcriptase inhibitors among persons infected with human immunodeficiency virus type 1 subtype circulating recombinant form 02_AG in Ghana and on antiretroviral therapy
title_full_unstemmed High resistance to reverse transcriptase inhibitors among persons infected with human immunodeficiency virus type 1 subtype circulating recombinant form 02_AG in Ghana and on antiretroviral therapy
title_short High resistance to reverse transcriptase inhibitors among persons infected with human immunodeficiency virus type 1 subtype circulating recombinant form 02_AG in Ghana and on antiretroviral therapy
title_sort high resistance to reverse transcriptase inhibitors among persons infected with human immunodeficiency virus type 1 subtype circulating recombinant form 02_ag in ghana and on antiretroviral therapy
topic 4850
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7035011/
https://www.ncbi.nlm.nih.gov/pubmed/32049783
http://dx.doi.org/10.1097/MD.0000000000018777
work_keys_str_mv AT deletsuselased highresistancetoreversetranscriptaseinhibitorsamongpersonsinfectedwithhumanimmunodeficiencyvirustype1subtypecirculatingrecombinantform02aginghanaandonantiretroviraltherapy
AT mainaedwardk highresistancetoreversetranscriptaseinhibitorsamongpersonsinfectedwithhumanimmunodeficiencyvirustype1subtypecirculatingrecombinantform02aginghanaandonantiretroviraltherapy
AT quayeosbourne highresistancetoreversetranscriptaseinhibitorsamongpersonsinfectedwithhumanimmunodeficiencyvirustype1subtypecirculatingrecombinantform02aginghanaandonantiretroviraltherapy
AT ampofowilliamk highresistancetoreversetranscriptaseinhibitorsamongpersonsinfectedwithhumanimmunodeficiencyvirustype1subtypecirculatingrecombinantform02aginghanaandonantiretroviraltherapy
AT awandaregordona highresistancetoreversetranscriptaseinhibitorsamongpersonsinfectedwithhumanimmunodeficiencyvirustype1subtypecirculatingrecombinantform02aginghanaandonantiretroviraltherapy
AT bonneyevelyny highresistancetoreversetranscriptaseinhibitorsamongpersonsinfectedwithhumanimmunodeficiencyvirustype1subtypecirculatingrecombinantform02aginghanaandonantiretroviraltherapy